Skip to main content
Smart Investors Daily
EO

NASDAQ · EOLS

Evolus, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$6.52

Down-$0.48 (-6.86%)

Updated Nov 22, 2026, 8:24 PM

SID Score

4.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
448.23M
P/E ratio
-7.64
Dividend yield
0.00%
52-week range
$3.86 – $9.31
Volume
813.65K
Avg. volume
1.3M

Price performance · EOLS

EOLS price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 20, 2026

EOLS closed at $6.52 after 20 trading sessions, down 9.07% for the selected period.

Last close
$6.52
Period change
-9.07%
Period low
$6.52
Period high
$7.64
Daily close
View OHLC price history
EOLS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 20, 2026$6.85$7.19$6.50$6.52813.65K
Nov 19, 2026$7.03$7.2146$6.93$7.00870.98K
Nov 18, 2026$6.68$7.09$6.55$7.07802.52K
Nov 17, 2026$6.63$6.73$6.30$6.69670.7K
Nov 16, 2026$6.90$7.03$6.615$6.63641.08K
Nov 13, 2026$7.18$7.18$6.85$6.96455.37K
Nov 12, 2026$7.38$7.65$7.15$7.18737.09K
Nov 11, 2026$6.87$7.44$6.85$7.421.29M
Nov 10, 2026$6.97$7.00$6.63$6.815.82M
Nov 9, 2026$6.88$7.04$6.72$6.981.15M
Nov 6, 2026$6.74$6.92$6.57$6.8051.52M
Nov 5, 2026$6.64$7.27$6.412$6.7952.13M
Nov 4, 2026$7.51$7.6501$7.33$7.47849.82K
Nov 3, 2026$7.17$7.415$7.17$7.37440.66K
Nov 2, 2026$7.34$7.44$7.15$7.16716.09K
Oct 30, 2026$7.48$7.56$7.235$7.35794.43K
Oct 29, 2026$7.75$7.83$7.38$7.52789.23K
Oct 28, 2026$7.38$7.705$7.30$7.635671.4K
Oct 27, 2026$7.18$7.37$7.07$7.37602.1K
Oct 26, 2026$7.06$7.19$6.90$7.17430.11K

Latest EOLS news

The latest Smart Investors Daily articles mentioning EOLS.

EOLS research

Overview

Company profile and research snapshot.

Company profile

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$19.00
Implied upside
—
Analysts
—
EOLS recent ratings
DateFirmRatingTarget
Nov 5, 2026BTIGBuy—
Aug 25, 2026HC Wainwright & Co.Buy—
Jun 17, 2026BTIGBuy—
Mar 4, 2026BTIGBuy—
Feb 3, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.